Enhancing disease selectivity of therapeutic antibodies for improved clinical efficacy by targeted binding bias and MOA modulation
22 Sep 2025
Target Selection & Mechanisms of Action
- How has epitope or conformation-specific binding bias improved the therapeutic index of antibody drugs like Cetuximab?
- How does MOA modulation lead to distinct efficacy over toxicity for the same target, as seen in CTLA-4?
- To what extent can receptor-biased antibodies help in minimizing systemic toxicity?
- How can we integrate binding bias and MOA modulation to improve clinical efficacy for next-generation therapeutic antibodies?
Industry Expert
